Looks like you’re on the UK site. Choose another location to see content specific to your location
Janssen’s Imbruvica recommended by NICE for new leukaemia indication
Janssen has received a recommendation from the UK's National Institute for Health and Care Excellence (NICE) for its drug Imbruvica to be used in a new leukaemia indication.
The regulator has issued technology appraisal guidance recommending Imbruvica for the treatment of chronic lymphocytic leukaemia in adult patients who have already been treated with one prior therapy, or those for whom chemotherapy is not suitable.
Developed in collaboration with Pharmacyclics, the drug has also been shown in phase III trials to offer potential as a first-line treatment, though it is currently only approved in the UK for first-line use in patients with 17p deletion or TP53 mutations.
The decision from NICE means that chronic lymphocytic leukaemia patients in England will be able to access Imbruvica through the NHS.
Jennifer Lee, director of health economics, market access and reimbursement and advocacy at Janssen UK, said: "Janssen is dedicated to ensuring that patients with blood cancer have access to the most effective and innovative therapies, and we keenly await a similar positive decision by NICE for patients with mantle cell lymphoma and Waldenstrom's macroglobulinemia."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard